Asset
Camibirstat
Foghorn Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04891757 | phase1 | active_not_recruiting | 2021-06-14 | 2025-09-01 | Foghorn Therapeutics Inc. | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies |
| NCT04879017 | phase1 | terminated | 2021-05-11 | 2023-11-30 | Foghorn Therapeutics Inc. | FHD-286 in Subjects With Metastatic Uveal Melanoma |
FDA applications (0)
This company has no applications containing this asset.